Graham Capital Management L.P. Acquires 20,347 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Graham Capital Management L.P. increased its stake in Ultragenyx Pharmaceutical by 34.4% during the first quarter, bringing its total holdings to approximately 79,476 shares worth about $2.88 million.
• Several other institutional investors also expanded their positions, with GAMMA Investing LLC growing its holdings by 76.2%, reflecting strong institutional interest in the company.
• Ultragenyx reported a loss of ($1.17) per share for the last quarter, better than analysts' expectations, with revenue increasing 13.2% from the previous year.

Graham Capital Management L.P. increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 34.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 79,476 shares of the biopharmaceutical company's stock after purchasing an additional 20,347 shares during the quarter. Graham Capital Management L.P. owned approximately 0.08% of Ultragenyx Pharmaceutical worth $2,878,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in RARE. California State Teachers Retirement System lifted its holdings in shares of Ultragenyx Pharmaceutical by 0.3% during the fourth quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company's stock worth $3,284,000 after buying an additional 268 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 323 shares during the last quarter. Xponance Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 2.8% during the first quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock worth $455,000 after buying an additional 347 shares during the last quarter. BOKF NA lifted its holdings in shares of Ultragenyx Pharmaceutical by 5.0% during the fourth quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock worth $336,000 after buying an additional 382 shares during the last quarter. Finally, Oak Ridge Investments LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 2.3% during the first quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company's stock worth $643,000 after buying an additional 395 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the transaction, the director owned 15,344 shares in the company, valued at approximately $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Trading Up 1.7%

Ultragenyx Pharmaceutical stock traded up $0.54 during mid-day trading on Friday, hitting $31.82. The stock had a trading volume of 1,325,361 shares, compared to its average volume of 1,301,378. The stock has a 50-day simple moving average of $30.49 and a two-hundred day simple moving average of $34.94. The stock has a market capitalization of $3.07 billion, a PE ratio of -5.75 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a 12 month low of $25.81 and a 12 month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.10. The business had revenue of $166.50 million for the quarter, compared to analysts' expectations of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm's quarterly revenue was up 13.2% compared to the same quarter last year. During the same quarter last year, the business earned ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Wedbush cut their target price on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research note on Monday, July 14th. HC Wainwright upgraded shares of Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 target price on the stock in a research report on Monday, July 28th. Morgan Stanley decreased their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, July 14th. Guggenheim reiterated a "buy" rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Finally, William Blair initiated coverage on Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price objective for the company. Eleven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $81.50.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.